이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Staidson (Beijing) BioPharmaceuticals 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Wang Chao

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.9yrs
CEO 소유권	0.08%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4.4yrs

최근 관리 업데이트

Recent updates

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

Mar 18

CEO

Wang Chao (42 yo)

2.9yrs

테뉴어

CN¥1,707,100

보상

Mr. Wang Chao is General Manager of Staidson (Beijing) BioPharmaceuticals Co. Ltd. from August 2021.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhi Wen Zhou	Chairman	15.2yrs	CN¥1.28m	1.1% CN¥ 29.5m
Tao Li	Supervisor	13.4yrs	CN¥168.10k	데이터 없음
Hongshan Zhang	Chairman of Supervisory Board	5.8yrs	CN¥240.00k	0.098% CN¥ 2.6m
Rong Qin Zhang	Non-Independent Director	5.8yrs	CN¥1.70m	0.21% CN¥ 5.5m
Ying Sun	Independent Director	5.8yrs	CN¥136.80k	데이터 없음
Lianchun Yang	Non-Independent Director	2.9yrs	CN¥1.60m	0.075% CN¥ 2.0m
Li Zhao	Independent Director	2.9yrs	CN¥136.80k	데이터 없음
Jiajun Zhao	Independent Director	2.9yrs	CN¥136.80k	데이터 없음
Hong Zheng	Employee Supervisor	2.9yrs	데이터 없음	0.024% CN¥ 642.8k
Xiaoyan Wang	Director	1.8yrs	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: 300204 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

Staidson (Beijing) BioPharmaceuticals 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

High number of new directors

Recent updates

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

First quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.10 loss in 1Q 2023)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

Full year 2023 earnings released: CN¥0.84 loss per share (vs CN¥0.41 loss in FY 2022)

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

New major risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.15 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.14 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.41 loss per share (vs CN¥0.29 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.14 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.094 loss in 2Q 2021)

Full year 2021 earnings: EPS and revenues miss analyst expectations

High number of new directors

Third quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.05 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.094 loss per share (vs CN¥0.11 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥8.02

New 90-day low: CN¥8.59

New 90-day low: CN¥9.90

Third quarter earnings released

New 90-day low: CN¥10.52

New 90-day low: CN¥10.73

First half earnings released

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥13.02

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령